tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jul 29;10(8):1208.
doi: 10.3390/vaccines10081208.
Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants
Yuntao Zhang[SUP] 1 2 [/SUP], Xiaotong Zheng[SUP] 1 [/SUP], Wang Sheng[SUP] 3 [/SUP], Hongyang Liang[SUP] 1 [/SUP], Yuxiu Zhao[SUP] 1 [/SUP], Xiujuan Zhu[SUP] 1 [/SUP], Rong Yang[SUP] 1 [/SUP], Yadan Zhang[SUP] 1 [/SUP], Xiaofei Dong[SUP] 1 [/SUP], Weidong Li[SUP] 1 [/SUP], Fei Pei[SUP] 1 [/SUP], Ling Ding[SUP] 1 [/SUP], Zhen Chang[SUP] 1 [/SUP], Li Deng[SUP] 1 [/SUP], Guangying Yuan[SUP] 1 [/SUP], Zhaona Yang[SUP] 1 [/SUP], Di Zhu[SUP] 1 [/SUP], Xiaoming Yang[SUP] 1 2 [/SUP], Hui Wang[SUP] 1 [/SUP]
Affiliations
Abstract
Since the beginning of the COVID-19 pandemic, numerous variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged, including five variants of concern (VOC) strains listed by the WHO: Alpha, Beta, Gamma, Delta and Omicron. Extensive studies have shown that most of these VOC strains, especially the currently dominant variant Omicron, can escape the host immune response induced by existing COVID-19 vaccines to different extents, which poses considerable risk to the health of human beings around the world. In the present study, we developed a vaccine based on inactivated SARS-CoV-2 and an adjuvant consisting of aluminum hydroxide (alum) and CpG. The immunogenicity and safety of the vaccine were investigated in rats. The candidate vaccine elicited high titers of SARS-CoV-2-spike-specific IgG antibody and neutralizing antibody in immunized rats, which not only neutralize the original SARS-CoV-2, but also showed great cross-neutralization activity against the Beta, Delta and Omicron variants.
Keywords: CpG; Omicron; SARS-CoV-2; immunogenicity; inactivated vaccine; safety.
. 2022 Jul 29;10(8):1208.
doi: 10.3390/vaccines10081208.
Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants
Yuntao Zhang[SUP] 1 2 [/SUP], Xiaotong Zheng[SUP] 1 [/SUP], Wang Sheng[SUP] 3 [/SUP], Hongyang Liang[SUP] 1 [/SUP], Yuxiu Zhao[SUP] 1 [/SUP], Xiujuan Zhu[SUP] 1 [/SUP], Rong Yang[SUP] 1 [/SUP], Yadan Zhang[SUP] 1 [/SUP], Xiaofei Dong[SUP] 1 [/SUP], Weidong Li[SUP] 1 [/SUP], Fei Pei[SUP] 1 [/SUP], Ling Ding[SUP] 1 [/SUP], Zhen Chang[SUP] 1 [/SUP], Li Deng[SUP] 1 [/SUP], Guangying Yuan[SUP] 1 [/SUP], Zhaona Yang[SUP] 1 [/SUP], Di Zhu[SUP] 1 [/SUP], Xiaoming Yang[SUP] 1 2 [/SUP], Hui Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 36016098
- DOI: 10.3390/vaccines10081208
Abstract
Since the beginning of the COVID-19 pandemic, numerous variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged, including five variants of concern (VOC) strains listed by the WHO: Alpha, Beta, Gamma, Delta and Omicron. Extensive studies have shown that most of these VOC strains, especially the currently dominant variant Omicron, can escape the host immune response induced by existing COVID-19 vaccines to different extents, which poses considerable risk to the health of human beings around the world. In the present study, we developed a vaccine based on inactivated SARS-CoV-2 and an adjuvant consisting of aluminum hydroxide (alum) and CpG. The immunogenicity and safety of the vaccine were investigated in rats. The candidate vaccine elicited high titers of SARS-CoV-2-spike-specific IgG antibody and neutralizing antibody in immunized rats, which not only neutralize the original SARS-CoV-2, but also showed great cross-neutralization activity against the Beta, Delta and Omicron variants.
Keywords: CpG; Omicron; SARS-CoV-2; immunogenicity; inactivated vaccine; safety.